Non-Invasive Testing for Coronary Artery Disease

Dr. Uprety discusses the current role of non-invasive testing for coronary artery disease, highlighting evidence-based diagnostic strategies and the appropriate use of imaging modalities to improve early detection, risk stratification, and clinical decision-making.

May 18, 2026

Sentara

Overview

This report discusses the role of non-invasive testing in diagnosing coronary artery disease (CAD), emphasizing the use of imaging modalities for early detection and risk stratification. Evidence-based strategies are highlighted to improve clinical decision-making.

Background

Coronary artery disease (CAD) is a leading cause of morbidity and mortality globally, necessitating effective diagnostic strategies. Non-invasive testing, particularly coronary computed tomographic angiography (CCTA), plays a crucial role in evaluating patients with suspected CAD. Understanding the appropriate use of these imaging modalities is essential for optimizing patient outcomes.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

CCTA is recommended as a first-line diagnostic tool for symptomatic patients with low-to-moderate pretest likelihood of obstructive CAD.
Coronary artery calcium scoring can aid in reclassifying patients at low likelihood of CAD.
Functional imaging is advised for patients with moderate-to-high likelihood of CAD to diagnose ischemia and assess cardiovascular event risk.
Invasive evaluation is warranted in cases with high-risk imaging features, such as severe multivessel disease.
The SCOT-HEART trial demonstrated that CCTA can reduce coronary heart disease death or non-fatal myocardial infarction without increasing revascularization rates.

Clinical Implications

Healthcare professionals should utilize CCTA and calcium scoring judiciously based on pretest likelihood to enhance diagnostic accuracy. Incorporating these non-invasive tests into clinical practice can improve risk stratification and guide management decisions effectively.

Conclusion

Non-invasive testing for CAD, particularly through CCTA and calcium scoring, is vital for early detection and improved patient outcomes. Adhering to established guidelines will facilitate optimal use of these diagnostic modalities.